Work

Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

Year: 2015

Type: article

Source: American Journal of Kidney Diseases

DOI: 10.1053/j.ajkd.2015.02.324

Authors: David M. Charytan, Eldrin F. Lewis, Akshay S. Desai, Larry A. Weinrauch, Peter Ivanovich, Robert D. Toto, Brian Claggett, Jiankang Liu, L. Howard Hartley, Peter Finn, Ajay K. Singh, Andrew S. Levey, Marc A. Pfeffer, John J.V. McMurray, Scott D. Solomon

Institutions: Brigham and Women's Hospital, Northwestern University, The University of Texas Southwestern Medical Center, Tufts University, University of Glasgow, Harvard University

Language: English

Topic: Erythropoietin and Anemia Treatment

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Society of Nephrology, Amgen, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases

Awards: Optimizing Revascularization of Coronary Artery Disease in Chronic Kidney Disease, Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRD, NO, myocardial fibrosis, and microvascular rarefaction in ESRD: Pilot Studies, CABG and PCI for the Treatment of CAD in Individuals with CKD

OpenAlex ID: W2065663647

FWCI: 3.142

Cites: 28

Cited by: 35

Related to: 10